















Supplementary Fig. S1. Scatter plots of the causal effect of metabolites on VTE









Succinylcarnitine




(16 or 17)-methylstearate (a19:0 or i19:0)




Linoleoylcarnitine (C18:2)




2-piperidinone




Behenoyl sphingomyelin (d18:1/22:0)




Tricosanoyl sphingomyelin (d18:1/23:0)




Gamma-glutamyl-alpha-lysine




Sphingomyelin (d18:2/24:2)




2-butenoylglycine





Trans-2-hexenoylglycine



4-hydroxyphenylpyruvate



Choline



MR Test

